Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer
Advanced Science · 2026-11 · 13 (62)
DOI: 10.1002/advs.77249 ↗At a glance
Journal article in Advanced Science, published online on 2026-08-20. Written by Bo Chen and 10 co-authors. Institution: Department of General Surgery, Department of Medical Oncology, Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Scien…. Major MEDLINE topics: Paclitaxel, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents, Phytogenic. 143 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Nature Science Foundation of China, Anhui Provincial Hospital, Health Research Program of Anhui.
Abstract (original language)
Drug resistance in solid tumors has emerged as a critical challenge, with limited effective therapeutic options available. In this study, we find that chemotherapy induces an increased tumor neoantigens burden (TNB) in breast cancer patients and both non‐resistant and chemo‐resistant triple‐negative breast cancer 4T1 tumor‐bearing mice. Consistently, proteomic analysis reveals that tumor antigens derived from in vitro chemotherapy‐treated paclitaxel (PTX)‐resistant 4T1 cells (chemo‐rAg) are enriched in damage‐associated molecular patterns and neoantigens, highlighting their potential to elicit antitumor immunity against chemo‐resistant tumors. Based on these findings, we utilize the feature of PTX resistance and develop a nanovaccine incorporating chemo‐rAg and a prodrug of a toll‐like receptor 7 (TLR7) agonist. In preclinical mouse models, the nanovaccine effectively suppresses PTX‐resistant 4T1 tumor growth, and it also reverses the innate resistance of immune checkpoint inhibitors. Notably, the therapeutic benefit of the nanovaccine is augmented by chemotherapy, which facilitates in situ release of tumor antigens. These results suggest that a chemo‐rAg‐based nanovaccine represents a promising strategy based on the ′like cures like' principle to overcome drug resistance by utilizing the characteristic of the drug resistance itself.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of General Surgery, Department of Medical Oncology, Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei…
- Department of Bio-X Interdisciplinary Science at Hefei National Laboratory (HFNL) for Physical Science at the Microscale, University of Science and Technology of China, Hefei, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- School of Chemistry and Materials Science, University of Science and Technology of China, Hefei, China.
- State Key Laboratory of Immune Response and Immunotherapy, Center for Advanced Interdisciplinary Science & Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei…
ORCID profiles: Yuanzeng Min
Funding
- National Nature Science Foundation of China
- Anhui Provincial Hospital
- Health Research Program of Anhui
- The Strategic Priority Research Program, the Chinese Academy of Sciences
- the Institute of Health and Medicine, Hefei Comprehensive National Science Center
- the Natural Science Foundation of China
Cite
APA
Chen, B., Wang, Y., Li, T., Guo, C., Xie, Z., Zhang, Z., Han, X., Wang, W., Wang, J., Ma, X., & Min, Y. (2026). Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer. Advanced Science, 13(62). https://doi.org/10.1002/advs.77249
Vancouver
Chen B, Wang Y, Li T, Guo C, Xie Z, Zhang Z, et al. Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2026;13(62). doi:10.1002/advs.77249
BibTeX
@article{Chen2026,
author = {Chen, Bo and Wang, Yangyi and Li, Tingting and Guo, Changqing and Xie, Zhe and Zhang, Zhixian and Han, Xinghua and Wang, Wei and Wang, Jian and Ma, Xiaopeng and Min, Yuanzeng},
title = {Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {62},
doi = {10.1002/advs.77249}
}
EUVIMED